Stenocare A/S reaffirmed sales guidance for the fourth quarter of 2022 and provides sales guidance for the year 2023. The company confirmed its sales guidance. On March 10, 2022, the company issued guidance that it would reach a quarterly sales run rate of DKK 4 million - DKK 5 million by end of 2022, corresponding to an annual sale of DKK 16 million - DKK 20 million or more in 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 DKK | -3.29% | -0.96% | +62.20% |
05-23 | Stenocare A/S Launches Next Generation Medical Cannabis Oil Product in Australia | CI |
05-02 | Stenocare A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+62.20% | 11.2M | |
+41.50% | 6.2B | |
-22.89% | 4.1B | |
+9.36% | 3.41B | |
-19.39% | 2.83B | |
-11.05% | 2.29B | |
+45.24% | 1.93B | |
-7.51% | 1.52B | |
+46.81% | 1.51B | |
-18.04% | 1.49B |
- Stock Market
- Equities
- STENO Stock
- News Stenocare A/S
- Stenocare A/S Reaffirms Sales Guidance for the Fourth Quarter of 2022 and Provides Sales Guidance for the Year 2023